LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S.
Forbes contributors publish independent expert analyses and insights. Stuart Anderson writes about immigration, business and globalization. Immigration data on the arrival of international students in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results